C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 26.6 PLN 2.31% Market Closed
Market Cap: 1.4B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celon Pharma SA
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Cash Interest Paid
zł2.3m
CAGR 3-Years
47%
CAGR 5-Years
67%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
8.66 PLN
Overvaluation 67%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Cash Interest Paid?
Cash Interest Paid
2.3m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Cash Interest Paid amounts to 2.3m PLN.

What is Celon Pharma SA's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
67%

Over the last year, the Cash Interest Paid growth was -2%. The average annual Cash Interest Paid growth rates for Celon Pharma SA have been 47% over the past three years , 67% over the past five years .

Back to Top